Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03284723 · ClinicalTrials.gov registry record · Phase 1
PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT03284723 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 95 participants.
The verdict
NCT03284723, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive and negative breast and gastric cancer (HER2 positive only and gastric were studied in Part 1A only). The study will expand to look at selected doses in patients with HER2 positive and negative breast cancer.
Interventions
- DRUG PF-06804103
- DRUG PF-06804103 + Palbociclib +Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2021-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03284723
The ClinicalTrials.gov registry entry for NCT03284723 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which PF-06804103 is the first listed.
NCT03284723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03284723 about?
NCT03284723 is a clinical study titled "PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors". The study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of PF-06804103 in patients with HER2 positive and negative breast and gastric cancer (HER2 positive only and gastric were studied in Part 1A only). The study will expand to look at selected doses in patient...
What is the current status of trial NCT03284723?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2017-11-01. Estimated completion is 2021-08-31.
What interventions are being tested in trial NCT03284723?
The interventions under investigation include: PF-06804103 (DRUG), PF-06804103 + Palbociclib +Letrozole (DRUG).
Who is sponsoring clinical trial NCT03284723?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.